Diabetes Care, Vol 21, Issue 9 1408-1413, Copyright © 1998 by American Diabetes Association

ARTICLES

Effects of changing diagnostic criteria on the risk of developing diabetes

SF Dinneen, D Maldonado, CL Leibson, GG Klee, H Li, LJ Melton and RA Rizza
Division of Endocrinology and Metabolism, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA. dinneen.sean@mayo.edu

OBJECTIVE: The American Diabetes Association (ADA) has recommended that the fasting plasma glucose (FPG) level used to diagnose diabetes be changed from 7.8 mmol/l (the level recommended by the National Diabetes Data Group [NDDG] in 1979) to 7.0 mmol/l. We examined the impact of this change on rates of progression to overt diabetes from different levels of FPG. RESEARCH DESIGN AND METHODS: Using the laboratory database of Mayo Clinic, we assembled a cohort of 8,098 nondiabetic Olmsted County residents 40 years of age or older on 1 July 1983. Subjects were followed for a median of 9 years. RESULTS: Among 7,567 individuals with follow-up FPG data, 778 (10.3%) progressed to ADA diabetes and 513 (6.8%; P < 0.0001) progressed to NDDG diabetes. The risk of developing ADA diabetes was 7, 19, and 39% for individuals with initial FPG values in the ranges of <5.6, 5.6-6.0, and 6.1-6.9 mmol/l, respectively. For progression to NDDG diabetes, the respective risks were 3, 11, and 25%. A clear gradient of risk was observed within the "normal" range of FPG (<5.6 mmol/l). Among the 793 individuals who developed ADA diabetes, 222 (29%) developed NDDG diabetes simultaneously and 291 (37%) developed NDDG diabetes later. In all FPG subgroups, progression to ADA diabetes occurred approximately 7 years sooner than progression to NDDG diabetes. CONCLUSIONS: The baseline level of FPG is a major predictor of an individual's risk of developing diabetes. The proposed change in the diagnostic criteria for diabetes will lead to earlier diagnosis among individuals who are destined to develop the disease.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. A. Sloan, D. Belsky, D. Ruiz Jr, and P. Lee Changes in Incidence of Diabetes Mellitus-Related Eye Disease Among US Elderly Persons, 1994-2005 Arch Ophthalmol, November 1, 2008; 126(11): 1548 - 1553. [Abstract] [Full Text] [PDF]

				F. A. Sloan, M. A. Bethel, D. Ruiz Jr, A. H. Shea, and M. N. Feinglos The Growing Burden of Diabetes Mellitus in the US Elderly Population Arch Intern Med, January 28, 2008; 168(2): 192 - 199. [Abstract] [Full Text] [PDF]

				Y. S. Levitzky, M. J. Pencina, R. B. D'Agostino, J. B. Meigs, J. M. Murabito, R. S. Vasan, and C. S. Fox Impact of Impaired Fasting Glucose on Cardiovascular Disease: The Framingham Heart Study J. Am. Coll. Cardiol., January 22, 2008; 51(3): 264 - 270. [Abstract] [Full Text] [PDF]

				G. A. Nichols, T. A. Hillier, and J. B. Brown Progression From Newly Acquired Impaired Fasting Glucose to Type 2 Diabetes: Response to Dinneen and Rizza Diabetes Care, July 1, 2007; 30(7): e80 - e80. [Full Text] [PDF]

				G. Bock, E. Chittilapilly, R. Basu, G. Toffolo, C. Cobelli, V. Chandramouli, B. R. Landau, and R. A. Rizza Contribution of Hepatic and Extrahepatic Insulin Resistance to the Pathogenesis of Impaired Fasting Glucose: Role of Increased Rates of Gluconeogenesis Diabetes, June 1, 2007; 56(6): 1703 - 1711. [Abstract] [Full Text] [PDF]

				M. A. Bethel, F. A. Sloan, D. Belsky, and M. N. Feinglos Longitudinal Incidence and Prevalence of Adverse Outcomes of Diabetes Mellitus in Elderly Patients Arch Intern Med, May 14, 2007; 167(9): 921 - 927. [Abstract] [Full Text] [PDF]

				G. Bock, C. Dalla Man, M. Campioni, E. Chittilapilly, R. Basu, G. Toffolo, C. Cobelli, and R. Rizza Effects of Nonglucose Nutrients on Insulin Secretion and Action in People With Pre-Diabetes Diabetes, April 1, 2007; 56(4): 1113 - 1119. [Abstract] [Full Text] [PDF]

				G. Bock, C. Dalla Man, M. Campioni, E. Chittilapilly, R. Basu, G. Toffolo, C. Cobelli, and R. Rizza Pathogenesis of Pre-Diabetes: Mechanisms of Fasting and Postprandial Hyperglycemia in People With Impaired Fasting Glucose and/or Impaired Glucose Tolerance Diabetes, December 1, 2006; 55(12): 3536 - 3549. [Abstract] [Full Text] [PDF]

				A.-M. Salmasi and M. Dancy The Glucose Tolerance Test, But Not HbA 1c, Remains the Gold Standard in Identifying Unrecognized Diabetes Mellitus and Impaired Glucose Tolerance in Hypertensive Subjects Angiology, September 1, 2005; 56(5): 571 - 579. [Abstract] [PDF]

				E. Bonora, S. Kiechl, J. Willeit, F. Oberhollenzer, G. Egger, J. B. Meigs, R. C. Bonadonna, and M. Muggeo Population-Based Incidence Rates and Risk Factors for Type 2 Diabetes in White Individuals: The Bruneck Study Diabetes, July 1, 2004; 53(7): 1782 - 1789. [Abstract] [Full Text] [PDF]

				Q. Qiao, P. Jousilahti, J. Eriksson, and J. Tuomilehto Predictive Properties of Impaired Glucose Tolerance for Cardiovascular Risk Are Not Explained by the Development of Overt Diabetes During Follow-Up Diabetes Care, October 1, 2003; 26(10): 2910 - 2914. [Abstract] [Full Text] [PDF]

				J. B. Meigs, D. C. Muller, D. M. Nathan, D. R. Blake, and R. Andres The Natural History of Progression From Normal Glucose Tolerance to Type 2 Diabetes in the Baltimore Longitudinal Study of Aging Diabetes, June 1, 2003; 52(6): 1475 - 1484. [Abstract] [Full Text] [PDF]

				R G. Barr, D. M. Nathan, J. B. Meigs, and D. E. Singer Tests of Glycemia for the Diagnosis of Type 2 Diabetes Mellitus Ann Intern Med, August 20, 2002; 137(4): 263 - 272. [Abstract] [Full Text] [PDF]

				F. de Vegt, J. M. Dekker, A. Jager, E. Hienkens, P. J. Kostense, C. D. A. Stehouwer, G. Nijpels, L. M. Bouter, and R. J. Heine Relation of Impaired Fasting and Postload Glucose With Incident Type 2 Diabetes in a Dutch Population: The Hoorn Study JAMA, April 25, 2001; 285(16): 2109 - 2113. [Abstract] [Full Text] [PDF]